Biotech

All Articles

Actinogen's cortisol blocker fails stage 2 anxiety research study

.Actinogen Medical's cortisol blocker has actually skipped the major endpoint of a period 2 study in...

Bivictrix chooses going personal only technique to take ADC in to medical clinic

.Antibody-drug conjugates (ADCs) have gone to the facility of lots of a billion-dollar biobuck licen...

TPG bests up funds to $580M for assets around life sciences

.Property supervisor TPG, which has assisted biotechs like Sionna Therapies and Santa Ana Biography,...

Merck quits phase 3 TIGIT test in lung cancer for futility

.Merck &amp Co.'s TIGIT program has endured an additional misfortune. Months after shuttering a peri...

After a hard year, Exscientia folds up right into Recursion

.After a year defined by pipe cuts, the variation of its own CEO as well as discharges, Exscientia w...

Cullinan, after $25M offer, return bispecific to Port

.Cullinan Therapy was actually excited good enough along with Port BioMed's bispecific immune system...

A closer look at Tough Biotech's Intense 15

.In this full week's incident of "The Leading Line," our team're diving into Intense Biotech's annua...

Lilly deals with phase 2 failing of tau-targeting med

.The confetti is actually still flying from Eli Lilly's celebration commemorating the approval of Al...

Biogen CMO Maha Radhakrishnan participates in Sofinnova-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our roundup of considerable management hirings, shootin...

Lykos are going to ask FDA to reexamine its own decision observing rejection of MDMA treatment for trauma

.Complying with a poor revealing for Lykos Therapeutics' MDMA prospect for trauma at a latest FDA co...